Tandem Diabetes Care, Inc. (TNDM)
| Market Cap | 1.62B +113.9% |
| Revenue (ttm) | 1.04B +4.0% |
| Net Income | -63.32M |
| EPS | -0.93 |
| Shares Out | 69.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,458,175 |
| Open | 22.62 |
| Previous Close | 22.81 |
| Day's Range | 22.56 - 23.80 |
| 52-Week Range | 10.00 - 29.65 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 28.55 (+22.38%) |
| Earnings Date | Aug 6, 2026 |
About TNDM
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a pe... [Read more]
Financial Performance
In 2025, Tandem Diabetes Care's revenue was $1.01 billion, an increase of 7.93% compared to the previous year's $940.20 million. Losses were -$204.71 million, 113.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price target is $28.55, which is an increase of 22.38% from the latest price.
News
Tandem Diabetes price target lowered to $26 from $30 at RBC Capital
RBC Capital analyst Kendall Au lowered the firm’s price target on Tandem Diabetes (TNDM) to $26 from $30 and keeps an Outperform rating on the shares. Tandem delivered an in-line…
Tandem Diabetes price target raised to $40 from $35 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on Tandem Diabetes (TNDM) to $40 from $35 and keeps a Buy rating on the shares. The firm said Tandem delivered…
Tandem Diabetes price target raised to $21 from $17 at Citi
Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $21 from $17 and keeps a Neutral rating on the shares.
Tandem Diabetes Care Earnings Call Transcript: Q2 2026
Record Q2 with 10%+ pump shipment growth, 6% sales increase, and 57% gross margin. Pharmacy PayGo adoption reached 10% of U.S. sales, and Mobi Tubeless FDA submission sets up a major H2 launch. Guidance reaffirmed with highest margins expected in Q4.
Tandem Diabetes Care Slides: Q2 2026
Tandem Diabetes Care has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Tandem Diabetes Care Earnings release: Q2 2026
Tandem Diabetes Care released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Tandem Diabetes Care Quarterly report: Q2 2026
Tandem Diabetes Care has published its Q2 2026 quarterly earnings report on August 6, 2026.
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter end...
Tandem Diabetes Care Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Cana...
Tandem Diabetes resumed with a Neutral at UBS
UBS resumed coverage of Tandem Diabetes (TNDM) with a Neutral rating with a price target of $18, down from $22, as part of a broader note on U.S. Medical Supplies…
Tandem Diabetes price target lowered to $20 from $24 at Mizuho
Mizuho lowered the firm’s price target on Tandem Diabetes (TNDM) to $20 from $24 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical device…
Tandem Diabetes launches t:slim X2 compatibility with Abbott’s FreeStyle
Tandem Diabetes Care (TNDM) announced that the t:slim X2 insulin pump with Control-IQ+ automated insulin delivery, AID, technology is now compatible with Abbott’s (ABT) FreeStyle Libre 3 Plus continuo...
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in five EU countries.
Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial ...
Tandem Diabetes initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Kieran Ryan initiated coverage of Tandem Diabetes (TNDM) with a Hold rating and $15.50 price target The ongoing transition to pay-go pharmacy is a “transformational shift” to…
Tandem Diabetes Care Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The conference highlighted strong momentum in product innovation, including the CE Mark for pregnancy indication and the upcoming Mobi Tubeless launch. The pharmacy channel transition is progressing, aiming to reduce out-of-pocket costs and drive growth, while international expansion and new technology initiatives are set to further strengthen market position.
Tandem Diabetes receives CE Mark for expanded indications of AID systems
Tandem Diabetes (TNDM) Care announced receipt of CE mark for expanded indications of its automated insulin delivery systems in Europe. The t:slim X2 and Tandem Mobi insulin delivery systems running…
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #TandemMobi--Tandem Diabetes Care receives CE mark for AID systems in Europe to include use in type 1 diabetes during pregnancy and adults with type 2 diabetes.
Wells upgrades Tandem Diabetes on ‘transformational’ pharmacy model
Wells Fargo last night upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight with a price target of $27, up from $21. The company’s pharmacy model is “transformational and de-risking…
Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight with a $27 price target
Tandem Diabetes price target lowered to $17 from $22 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Tandem Diabetes (TNDM) to $17 from $22 and keeps a Neutral rating on the shares. The firm updated models in…
Tandem Diabetes price target lowered to $21 from $24 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Tandem Diabetes (TNDM) to $21 from $24 and keeps a Neutral rating on the shares. MedTech has experienced one of its weakest…
Tandem Diabetes Care Transcript: AGM 2026
The meeting covered six key proposals, including director elections, executive compensation, and amendments to governance documents. All proposals passed, and no questions were raised on meeting matters.
Tandem Diabetes price target lowered to $25 from $35 at BofA
BofA lowered the firm’s price target on Tandem Diabetes (TNDM) to $25 from $35 and keeps a Neutral rating on the shares. After having hosted 34 medtech companies last week…
Tandem Diabetes Care Transcript: Bank of America Global Healthcare Conference 2026
Record Q1 results were achieved amid major business model changes, including the PayGo pharmacy launch and direct international sales. Pharmacy channel coverage is expanding, new product launches like Mobi are set to drive growth, and profitability is improving with strong customer retention.